This article is part of a Chronicle. See more from this Chronicle
Robert Maness, Brian Segers, Apr 29, 2014
The Federal Trade Commission, as part of its ongoing enforcement of perceived anticompetitive abuse of the regulatory and legal structure in the pharmaceutical industry, has turned its gaze to branded pharmaceutical firms’ refusal to sell samples of restricted distribution products to firms seeking approval to market generic versions.
The types of restricted distribution arrangements
...THIS ARTICLE IS NOT AVAILABLE FOR IP ADDRESS 18.222.69.152
Please verify email or join us to access premium content!